Reduction in the colonization of central venous cannulae by mupirocin

R. L. R. Hill and M. W. Casewell

Department of Medical Microbiology, King’s College School of Medicine and Dentistry, Bessemer Road, London SE5 8RX, UK

Summary: In an in-vitro simulation of an intravascular cannula enclosed in a fibrin sheath, 0.03 mg l⁻¹ of mupirocin prevented significant colonization (> 15 colony forming units (cfu)) by two clinical isolates of Staphylococcus epidermidis and one each of S. saprophyticus, S. hominis and S. haemolyticus. This suggests that in vivo, where protein binding of mupirocin is 95–97%, 1 mg l⁻¹ of mupirocin at the cannula surface would be required to prevent colonization.

These results support the findings of our previously published prospective controlled trial, in which mupirocin applied to the insertion sites of 172 internal jugular cannulae reduced the rate of colonization of cannula tips to 5%, compared with 25% for the 186 controls (P<0.001). Of the 46 colonized cannula tips from 110 control patients, the same species was isolated from the skin of the insertion site in 67% and from the lumen flush in only 1.5%. Analysed by patient, mupirocin reduced the proportion of patients with colonized tips from 17% to 3% after 24 h of infection, and from 35 to 10% after 48 h (P=0.002). The use of agar containing charcoal, as a mupirocin neutralizer, and the incubation of tip-culture plates flooded with the Oxford staphylococcus, gave no evidence of carry over of mupirocin onto cannulae removed from mupirocin-treated patients.

Keywords: Intravenous cannulae; colonization; mupirocin; iodine; staphylococci.

Introduction

The proportion of central venous cannulae that give rise to septicaemia has been reported as 3.8–21%.1–5 Although there is controversy as to whether the skin or the cannula hub is the source of organisms,6 several studies have confirmed a correlation between organisms cultured from the skin of the insertion site and those subsequently isolated from the cannula tip.7–12 Suppression of skin flora at the insertion site is therefore essential, and Maki13 has recommended disinfection of the skin with tincture of iodine. In a placebo-controlled trial we recently showed that local application of mupirocin to the site of insertion of internal jugular cannulae markedly reduces colonization of the cannula tip;14 these results are reviewed here with some new supporting in-vitro data.
Materials and methods

In-vitro simulation

In vivo, the intravascular segment of the percutaneously inserted cannula becomes surrounded by a fibrin sheath which connects to the subcutaneous tract. In addition, it is thought that organisms from the skin at the insertion site enter the subcutaneous tract and reach the cannula tip by capillary action. The in-vitro arrangement shown in Figure 1 simulates the effect of mupirocin on the colonization of the cannula tip in the closed environment of a fibrin sheath. The procedure used was as follows:

1. Doubling dilutions of mupirocin from 1·0–0·004 mg l⁻¹ were made in 10 ml aliquots of Iso-sensitest broth (Unipath CM473) contained in 30 ml glass universal containers.

2. 25 mm segments of 16 gauge ‘Abbocath T’ (Abbott Laboratories) cannulae were immersed in broth with (test), or without (control), mupirocin.

3. For each experiment, test and control broths were inoculated with dilutions of overnight broth cultures of one of five test strains of coagulase-negative staphylococci. We used two clinical isolates of S. epidermidis (MICs 0·06 and 0·025 mg l⁻¹), and one each of S. saprophyticus (MIC 0·03 mg l⁻¹), S. hominis (MIC 0·12 mg l⁻¹) and S. haemolyticus (MIC 0·03 mg l⁻¹). The final inoculum was approximately 10² cfu ml⁻¹.

4. After incubation at 37°C for 18 h, cannula segments were removed from their broths and drained for 3 min on sterile filter paper.

Figure 1. The in-vitro simulation.
Mupirocin and intravenous cannulae

(5) Segments were then rolled back and forth five times on blood agar according to the method of Maki et al.17

Controlled trial of mupirocin for the reduction of colonization of internal jugular cannulae

In a prospective study reported previously in this Journal,14 218 cardiothoracic patients were randomized to receive skin preparation of the insertion site of 'Abbocath T' cannulae (inserted into the internal jugular vein) with tincture of iodine (108 controls) or tincture of iodine followed by application of sterile 2% calcium mupirocin ointment (110 test patients). Routine peri-operative chemoprophylaxis consisted of 80 mg of gentamicin plus 500 mg of flucloxacillin or 500 mg of erythromycin for 48 h. Cannulae were removed postoperatively, usually within 48 h of the operation, by a research control of infection nurse. At redressing and cannula removal, insertion sites were assessed for signs of local infection.

Before cannula removal, all traces of antibiotic ointment and iodine were removed from the insertion site. The skin was sampled for culture and then cleaned with an alcohol-impregnated swab. After removal of the cannula, 5 ml of broth was flushed through the lumen and sent with the cannula to the laboratory. The detailed microbiological methods have been described elsewhere18 and included semiquantitative culture of the tip and intracutaneous segments on blood agar according to the method of Maki et al.17 followed by enrichment cultures. The lumen flush was also cultured directly and by enrichment. The possibility of carry-over of mupirocin on to the removed cannulae was assessed by three methods during weeks 3–6 and 3–46 of the 37-week trial: firstly, by culture of 120 colonized cannula tips on blood agar with, and without, a neutralizer, namely 2% charcoal (Oxoid L9); 66 of these tips were from patients in the mupirocin group. Secondly, 120 skin swabs were also cultured on charcoal blood agar, 66 of which were from mupirocin-treated skin. Lastly, 0.5 ml of an overnight broth culture of mupirocin-sensitive Oxford staphylococcus, diluted to give a semi-confluent growth (see Hill et al.,14,18) was pipetted onto 120 incubated tip culture plates which were then re-incubated for 18 h and re-examined for zones of inhibition which, if present, might suggest the presence of mupirocin carried over at the time of inoculation with the cannula tip.

Results

In-vitro simulation

Cannula segments that had been immersed in control broths, without added mupirocin, yielded confluent growth from the rolled cannula segment. Figure 2 shows the influence of various concentrations of mupirocin on the recovery of each of the five test strains of coagulase-negative staphylococci from the cannula segments. At concentrations of 0.06 mg l⁻¹, none of the
Figure 2. Colony counts from roll plates of cannulae exposed for 18 h to increasing concentrations of mupirocin.

five strains were recovered after 18 h incubation with the cannulae. As the concentration of mupirocin decreased so the number of recoverable cfus for each strain increased. A concentration of 0.03 mg l\(^{-1}\) of mupirocin was also adequate to prevent significant colonization of the cannula segments (i.e. <15 cfus). However, at 0.015 mg l\(^{-1}\), 10 cfus of *S. hominis* and 220 cfus of strain B of *S. epidermidis* were recovered. In general, these differences seemed to correlate with the MIC of each organism: strain B of *S. epidermidis* had the highest MIC (0.025 mg l\(^{-1}\)) and the highest number of cfus recovered at each concentration of mupirocin, whereas *S. saprophyticus*, which had an MIC of 0.03 mg l\(^{-1}\), yielded the lowest number of recoverable cfus. However, there were some strain differences which did not follow the MIC. For example, strain A of *S. epidermidis*, which had an MIC of 0.06 mg l\(^{-1}\), yielded fewer cfus when exposed to 0.004 mg l\(^{-1}\) of mupirocin than did the *S. haemolyticus* which had a lower MIC of 0.03 mg l\(^{-1}\).
**Controlled trial**

The results of this trial have been reported elsewhere\(^{14,18}\) and the main findings will be summarized here along with some previously unpublished data. The influence of mupirocin on the main source of organisms for the colonization of cannula tips will be further considered.

There were 108 patients in the control group and 110 in the mupirocin group (test), from whom 186 and 172 cannulae, respectively, were obtained. The features of patients and cannulae in test and control groups were evenly matched.$^1$ Mupirocin reduced the proportion of patients with significantly colonized cannula tips (i.e. recovery of > 15 cfus) regardless of in-situ time (Table I). Within 24 h of insertion, 17% of control patients had colonized tips, compared with 3% of the test patients who had mupirocin applied to the insertion site. Table I also shows that the proportion of patients with colonized cannulae increased with in-situ time. By 48 h, 35% of control patients had colonized tips, and this increased to 66% for patients with cannulae in situ for 48–120 h. This increase with time was less marked for mupirocin-treated patients, of whom only 10% had colonized lines in situ for up to 48 h. For the 17 test patients whose cannulae were in situ for 48–120 h, none yielded > 15 cfu from their cannula tips.

Analysis by cannulae (Table II) also showed that mupirocin reduced cannula colonization, regardless of in-situ time. In the control group, the intracutaneous segments were more often colonized than the tips: 32 (45%) vs 24 (34%), respectively for cannulae in situ for > 24–48 h. However, in the mupirocin group, the colonization rates of tips and intracutaneous segments were similar: 10% vs 12% for tips and intracutaneous segments, respectively, for in-situ times of > 24–48 h. Only 6 (1.7%) of lumen flush cultures were positive, three in the test and three in the control groups.

The results for the 358 cannulae obtained from 218 patients are shown in Table III. Overall, mupirocin reduced the proportion of colonized tips from 25% to 5% ($P<0.001$). Even by enrichment culture of any segment there were fewer cannulae yielding growth in the mupirocin group (23%) compared with controls (64%) ($P<0.001$). There was no significant difference in the incidence of erythema or pus at the 183 puncture sites in the control group or in the 164 sites in the mupirocin group that were assessed for signs of local infection.

<table>
<thead>
<tr>
<th>In-situ time (h)</th>
<th>Control patients</th>
<th>Mupirocin patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>No. (%) with positive tip</td>
</tr>
<tr>
<td>&lt;24</td>
<td>98</td>
<td>16 (17)</td>
</tr>
<tr>
<td>24–&lt;48</td>
<td>68</td>
<td>24 (35)</td>
</tr>
<tr>
<td>48–120</td>
<td>9</td>
<td>6 (66)</td>
</tr>
</tbody>
</table>

Table I. **Patients with one or more significantly colonized cannula tips**
Table II. Significant colonization of cannula segments according to in-situ time

<table>
<thead>
<tr>
<th>Cannula segment</th>
<th>In-situ time (h)</th>
<th>Control group</th>
<th>Mupirocin group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tip</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;24</td>
<td>105</td>
<td>15</td>
<td>103</td>
<td>3</td>
</tr>
<tr>
<td>24-&lt;48</td>
<td>71</td>
<td>34</td>
<td>50</td>
<td>10</td>
</tr>
<tr>
<td>48-120</td>
<td>10</td>
<td>60</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td>Intracutaneous</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;24</td>
<td>105</td>
<td>23</td>
<td>103</td>
<td>5</td>
</tr>
<tr>
<td>24-&lt;48</td>
<td>71</td>
<td>45</td>
<td>50</td>
<td>12</td>
</tr>
<tr>
<td>48-120</td>
<td>10</td>
<td>70</td>
<td>19</td>
<td>10</td>
</tr>
<tr>
<td>Lumen flush</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;24</td>
<td>105</td>
<td>1</td>
<td>103</td>
<td>1</td>
</tr>
<tr>
<td>24-&lt;48</td>
<td>71</td>
<td>1</td>
<td>50</td>
<td>2</td>
</tr>
<tr>
<td>48-120</td>
<td>10</td>
<td>1</td>
<td>19</td>
<td>0</td>
</tr>
</tbody>
</table>

*NS = Not significant.

Table III. Outcome for 186 control cannulae and 172 that were mupirocin-treated

<table>
<thead>
<tr>
<th>No. of cannulae (%)</th>
<th>Controls</th>
<th>Mupirocin</th>
<th>Significance (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;15 cfu from tip</td>
<td>46 (25)</td>
<td>8 (5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Any segment +ve by enrichment</td>
<td>119 (64)</td>
<td>39 (23)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Associated with local signs</td>
<td>27 (15)</td>
<td>32 (20)</td>
<td>NS*</td>
</tr>
</tbody>
</table>

*NS = Not significant.

Coagulase-negative staphylococci were the most frequent isolates, accounting for 62% of isolates from the control group and 19% of those from the test group. Micrococci and corynebacteria each accounted for 8% of isolates from control cannulae and 5% from the test group. *Staphylococcus aureus* accounted for only 2% of isolates in the mupirocin group and 2% in the control group, whilst other organisms including the Enterobacteriaceae comprised 0.5-3.0%. For 31 (67%) of colonized cannula tips from control patients, the same species was also isolated from the skin of the insertion site. Only seven colonized cannulae (15%) yielded organisms that were also found in the lumen flush. For the test group the skin was identified as the source of organisms for only two cannulae. Both of these isolates were mupirocin resistant *S. epidermidis* that were isolated from the skin before treatment with mupirocin. For mupirocin-treated patients there was only one cannula for which the tip isolate could be found in the lumen flush.
Table IV. Influence of media on the rate of detection of significant colonization of cannula tips

|                           | Control  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of significantly colonized tips with greater growth on media containing:</td>
<td></td>
</tr>
<tr>
<td>Blood</td>
<td>13</td>
</tr>
<tr>
<td>Blood + charcoal</td>
<td>2</td>
</tr>
<tr>
<td>Mupirocin</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
</tbody>
</table>

Table IV shows that, of 120 cannulae, none yielded significant counts (> 15 cfu) on charcoal blood agar alone. One significantly colonized tip was detected only on blood agar. None of the 120 skin swabs were positive on the charcoal whilst negative on blood agar but two were positive only on blood agar. When flooded with the Oxford staphylococcus, none of the cannula tip plates gave inhibition zones to suggest carry over of mupirocin.

Discussion

Our results show clearly that mupirocin can prevent colonization of central venous cannulae. In-vitro models have previously been used to investigate the influence of antimicrobial substances on the colonization of intravascular cannulae, but our in-vitro experiments mimic more closely the static environment of an intravascular cannula enclosed by a fibrin sleeve that is seeded from skin-derived organisms. In vivo, skin organisms may gain access to the cannula tip by capillary action.

In our model, sub-inhibitory concentrations of mupirocin prevented significant colonization of central-venous cannula segments by five distinct strains of coagulase-negative staphylococci. This reduction of cannula colonization by sub-inhibitory concentrations has also been described for ciprofloxacin and fusidic acid. Sub-inhibitory concentrations of certain antibiotics are known to prevent bacterial adhesion, a prerequisite for colonization. Nevertheless, despite the possibility of beneficial sub-inhibitory effects, mupirocin did not prevent colonization of internal jugular cannulae by high-level mupirocin-resistant staphylococci derived from the insertion site in vivo. The effect of sub-inhibitory concentrations on more resistant organisms, and the effect of longer exposure times, warrants further investigation.

Microorganisms adhere to implanted surfaces via plasma-derived proteins which, for example, would be deposited on the surface of intravenous cannulae in vivo. Because mupirocin is 95–97% protein-bound (Hill & Casewell, unpublished observations) c.1·0 mg l⁻¹ will be required to yield 0·03 mg l⁻¹ of free mupirocin—the concentration
shown in this study that is required to prevent significant colonization with sensitive staphylococci. Determination of the half-life of mupirocin ointment at the cannula insertion site would give an indication of the maximum interval before re-application of the ointment that would ensure continuous delivery of adequate concentrations of mupirocin, i.e. >1.0 mg l⁻¹.

In our controlled trial, we applied ointment containing 2% calcium mupirocin (20 000 mg l⁻¹) directly to the puncture site in anticipation that sufficient mupirocin would diffuse down the subcutaneous tract to prevent colonization of the cannula tip. It was also envisaged that the addition of mupirocin would suppress any regrowth of skin flora. As skin disinfection has been shown to influence contamination of the cannula lumen,⁹ percutaneous insertion of the cannula through mupirocin might also decrease luminal contamination.

The results of the trial showed clearly that the application of mupirocin to the skin of the cannulation site after skin disinfection with tincture of iodine reduced significant colonization of cannulae inserted into the internal jugular vein from 25% to 5% (P<0.001).¹⁴,¹⁸ For the test and control groups, both patients and cannulae were well matched. Previous studies on topical antibiotic ointments have usually investigated more heterogeneous groups of patients and indicated that local application of antibiotic ointment confers little, if any, benefit³¹-³³ and may only be ‘suitable’ for peripheral lines.³⁴ Although the majority of the patients studied were cannulated for <48 h and were at low risk of acquiring a cannula-related bacteraemia, it is generally agreed that colonization is a prerequisite for bacteraemia and clinical cannula-related sepsis.³⁵,³⁶ The longer a colonized line is left in situ the greater the correlation of positive semi-quantitative cannula cultures with bacteraemia.³⁷,³⁸ In our study, mupirocin significantly reduced the proportion of patients with one or more colonized cannula tips regardless of in-situ time.

We took care to avoid carry over of ointment or iodine, at cannula removal. The use of agar containing charcoal, which served as a neutralizer³⁹ did not improve the positivity rate of tip or skin cultures, and its use was thus discontinued. Indeed, charcoal agar often reduced bacterial growth, possibly by indiscriminant absorption of nutrients. Inoculation of a mupirocin-sensitive staphylococcus on to tip culture plates after incubation also failed to reveal evidence of antibiotic carry-over.

The application of mupirocin to the insertion site did not result in the isolation of mupirocin-resistant organisms such as Pseudomonas or Candida spp. The isolates from cannula tips corresponded most often to those cultured from the skin at the insertion site, rather than to the infrequent isolates from the cannula lumen. Mupirocin greatly reduced the skin flora with a corresponding decrease in the number of colonized tips. This supports the view that the skin of the insertion site, rather than the lumen, is the main source of organisms for colonization of the tip.⁷-¹² However, we
Mupirocin and intravenous cannulae

recognize that the junction between the cannula hub and the giving-set may assume importance with frequent make-and-break connections, for example during parenteral nutrition and haemodialysis. We conclude that application of mupirocin to the insertion site reduces the colonization of internal jugular cannulae by sensitive staphylococci. In addition, we suggest mupirocin has marked potential for the reduction of cannula-related sepsis caused by staphylococci in high-risk patients.

References

17. Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying
R. L. R. Hill and M. W. Casewell


